American ginseng does not improve fatigue in multiple sclerosis: A single center randomized double-blind placebo-controlled crossover pilot study

E. Kim, M. Cameron, J. Lovera, L. Schaben, D. Bourdette, R. Whitham

Research output: Contribution to journalArticle

15 Scopus citations


This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.

Original languageEnglish (US)
Pages (from-to)1523-1526
Number of pages4
JournalMultiple Sclerosis Journal
Issue number12
StatePublished - Dec 2011



  • Panax
  • clinical trial
  • complementary therapies
  • fatigue
  • ginseng
  • multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this